Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 132   

Articles published

GSK 1,629.50 -11.50 (-0.70%)
price chart
Will Shingrix be GlaxoSmithKline plc's next blockbuster?
London-listed pharmaceutical giant GlaxoSmithKline(LSE: GSK) announced today that it has submitted a Biologics License Application (BLA) for its candidate shingles vaccine, Shingrix, to the United States Food and Drug Administration (FDA), seeking ...
GlaxoSmithKline plc (GSK) PT Raised to GBX 1800 at Credit Suisse Group AG
GlaxoSmithKline plc logo GlaxoSmithKline plc (LON:GSK) had its price target raised by investment analysts at Credit Suisse Group AG from GBX 1,440 ($17.55) to GBX 1,800 ($21.94) in a note issued to investors on Friday.
GlaxoSmithKline plc (GSK) Scheduled to Post Earnings on Wednesday  The Cerbat Gem
GlaxoSmithKline plc (GSK) Price Target Raised to GBX 1800 at Credit Suisse ...  Community Financial News
Which is the better buy? GlaxoSmithKline plc vs Shire plc
Shire(LSE: SHP) and GlaxoSmithKline(LSE: GSK) are two of the UK's premier pharmaceutical companies but over the past five years, their fortunes couldn't have been more different.
GlaxoSmithKline plc 15.4% Potential Upside Indicated by Investec
GlaxoSmithKline plc using EPIC/TICKER code LON:GSK has had its stock rating noted as 'Initiates/Starts' with the recommendation being set at 'BUY' today by analysts at Investec.
GlaxoSmithKline plc (GSK) PT Raised to GBX 1800  The Cerbat Gem
Ratings Change: Are Analysts Bearish GlaxoSmithKline plc (ADR) (NYSE:GSK ...  MoneyMakingArticles
A solid, defensive play for yield investors, but just what could sink GSK?
A decent defensive play and one for the yield investors is how one leading City broker described GlaxoSmithKline plc (LON:GSK) ahead of third-quarter figures next week.
GlaxoSmithKline PLC (GSK) Receives Consensus Rating of "Hold" from Brokerages
GlaxoSmithKline PLC logo GlaxoSmithKline PLC (NYSE:GSK) has received a consensus recommendation of “Hold” from the twenty-four brokerages that are presently covering the firm.
Glaxo Sells Stake in South Africa's Aspen for $619 Million
GlaxoSmithKline Plc ended its seven-year run as an investor in Aspen Pharmacare Holdings Ltd., selling the final portion of its stake in the South African company for about $619 million.
GlaxoSmithKline to sell remaining stake in Aspen  MarketWatch
Investors Spotlight: GlaxoSmithKline plc's (GSK)
GlaxoSmithKline plc's (GSK) witnessed a loss of -1.09% in recent trading period with closing price of $ 40.68. The company's last traded volume of 3.09 million shares as compared to it's an average volume of 2.68 million shares.
Better Buy: GlaxoSmithKline plc vs. Johnson & Johnson
GlaxoSmithKline (NYSE:GSK) and Johnson & Johnson (NYSE:JNJ) are giants in their field, and they've both earned well-deserved reputations for taking advantage of opportunities in the pharmaceutical industry that have turned into sizable profits.
GlaxoSmithKline to pay $20 million to settle US foreign bribery case  Reuters
Glaxo to Pay $20 Million SEC Fine Over Bribery in China  Bloomberg
GlaxoSmithKline plc 14.1% Potential Upside Indicated by Jefferies International
GlaxoSmithKline plc using EPIC/TICKER code LON:GSK had its stock rating noted as 'Reiterates' with the recommendation being set at 'BUY' today by analysts at Jefferies International.
GlaxoSmithKline plc (GSK) Given "Buy" Rating at Bryan, Garnier ...  BBNS
GlaxoSmithKline plc (GSK) Receives Consensus Rating of "Hold" from ...  Community Financial News